Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3
申请人:Max-Planck-Gesellschaft zur Förderung
der Wissenschaften e.V.
公开号:EP2851092A1
公开(公告)日:2015-03-25
The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.
[EN] PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3<br/>[FR] VACCINS SYNTHÉTIQUES SANS PROTÉINE ET SANS PEPTIDE CONTRE LE STREPTOCOCCUS PNEUMONIAE DE TYPE 3
申请人:MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V
公开号:WO2015040140A1
公开(公告)日:2015-03-26
The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.
[EN] IMPROVED PREPARATION OF VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3<br/>[FR] PRÉPARATION AMÉLIORÉE DE VACCINS CONTRE STREPTOCOCCUS PNEUMONIAE DE TYPE 3
申请人:MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V
公开号:WO2017178664A1
公开(公告)日:2017-10-19
The present invention relates to the preparation of a synthetic tetrasaccharide, hexasaccharide and octasaccharide representing part of the repeating unit of the Streptococcus pneumoniae type 3 capsular polysaccharide as well as conjugates thereof. Said conjugates are particularly useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae type 3. The disclosed synthetic method has the huge advantages over the state of the artsynthetic methods that intermediate products are crystalline, coupling reaction yields are higher, less reaction steps are required and purification of intermediate products is easier.